title: Cellular distribution of Glut-1 and Glut-5 in benign and malignant human prostate tissue.
abstract: Over-expression of hexose transporters (Gluts), specifically Glut-1, is a common event in human malignancies. In prostate cancer (CaP), however, expression of Gluts has been characterized poorly. In this study, expression and distribution of Glut-1 and Glut-5 proteins were characterized using immunohistochemistry in 76 specimens of benign prostate, 10 specimens of high-grade intraepithelial neoplasia (HGPIN), and 28 specimens of CaP. In addition, mRNA expression of Glut-2, Glut-7, Glut-9, and Glut-11 was analyzed in a set of five specimens of benign prostate and CaP. In benign prostate, Glut-1 localized to the basal cells and to the basolateral membrane of secretory/luminal epithelial cells. Glut-5, however, localized to the apical membrane of secretory/luminal epithelial cells. In HGPIN, Glut-1 was immunohistochemically undetectable. Glut-5, however, localized to the apical membrane of the neoplastic epithelial cells. In CaP, Glut-1 and Glut-5, were immunohistochemically undetectable. However, over-expression of GLUT1 was observed in some specimens of highly proliferative intraductal CaP. Glut-7, Glut-9, and Glut-11 mRNAs were detected in benign prostate and CaP, however, only Glut-11 mRNA was consistently up-regulated in CaP compared to benign prostate. Low levels of expression of Glut-1 protein in the majority of CaP could explain, at least in part, the limited clinical applicability of positron emission tomography using 2-[18F]-fluoro-2-deoxy-D-glucose for imaging CaP. Moreover, expression of Glut-5 in HGPIN suggested that fructose could be utilized as potential metabolic substrate in HGPIN. Understanding the molecular mechanisms involved in regulation/dysregulation of Gluts in CaP could provide insight in the understanding of hexose metabolism in CaP.
authors.affiliation: Departamento de Biología Celular, Universidad de Concepción, Concepción, Chile.
authors.forename: Karin
authors.initials: K
authors.lastname: Reinicke
authors.forename: Paula
authors.initials: P
authors.lastname: Sotomayor
authors.forename: Pedro
authors.initials: P
authors.lastname: Cisterna
authors.forename: Carolina
authors.initials: C
authors.lastname: Delgado
authors.forename: Francisco
authors.initials: F
authors.lastname: Nualart
authors.forename: Alejandro
authors.initials: A
authors.lastname: Godoy
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000378:metabolism*; D002462:Cell Membrane / Q000378:metabolism; D015870:Gene Expression; D051246:Glucose Transport Proteins, Facilitative / Q000235:genetics / Q000378:metabolism; D051272:Glucose Transporter Type 1 / Q000235:genetics / Q000378:metabolism*; D051296:Glucose Transporter Type 5 / Q000235:genetics / Q000378:metabolism*; D006801:Humans; D008297:Male; D008875:Middle Aged; D060787:Neoplasm Grading; D009928:Organ Specificity; D011467:Prostate / Q000378:metabolism* / Q000473:pathology; D019048:Prostatic Intraepithelial Neoplasia / Q000378:metabolism* / Q000473:pathology; D011471:Prostatic Neoplasms / Q000378:metabolism* / Q000473:pathology; D021381:Protein Transport
chemical_list: D014408:Biomarkers, Tumor; D051246:Glucose Transport Proteins, Facilitative; D051272:Glucose Transporter Type 1; D051296:Glucose Transporter Type 5; C495677:SLC2A1 protein, human; C495726:SLC2A5 protein, human